Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Beclometasone (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceuticals USA
- 26 Feb 2013 Secondary endpoint results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 09 Nov 2012 Results were presented at the Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in November 2012.
- 22 May 2012 Actual end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.